EAM Investors LLC Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

EAM Investors LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 222,377 shares of the company's stock, valued at approximately $754,000. EAM Investors LLC owned approximately 0.15% of Xeris Biopharma as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its stake in Xeris Biopharma by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company's stock worth $107,000 after buying an additional 2,954 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its position in shares of Xeris Biopharma by 6.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company's stock worth $227,000 after acquiring an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock valued at $78,000 after acquiring an additional 5,500 shares during the last quarter. Prudential Financial Inc. increased its stake in Xeris Biopharma by 23.4% in the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock valued at $125,000 after acquiring an additional 7,000 shares during the last quarter. Finally, Goldstein Advisors LLC raised its position in Xeris Biopharma by 24.2% during the fourth quarter. Goldstein Advisors LLC now owns 37,800 shares of the company's stock valued at $128,000 after purchasing an additional 7,375 shares in the last quarter. Institutional investors own 42.75% of the company's stock.

Insider Buying and Selling

In related news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.56% of the stock is owned by corporate insiders.

Xeris Biopharma Stock Down 0.7 %

Shares of XERS stock traded down $0.03 during mid-day trading on Wednesday, reaching $4.07. 1,067,808 shares of the stock traded hands, compared to its average volume of 1,862,673. The stock's fifty day simple moving average is $4.46 and its two-hundred day simple moving average is $3.71. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $6.07. The company has a market cap of $626.54 million, a price-to-earnings ratio of -9.04 and a beta of 1.37.

Analysts Set New Price Targets

Several brokerages have recently issued reports on XERS. Piper Sandler reiterated a "neutral" rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th. Leerink Partners increased their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, HC Wainwright reiterated a "buy" rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Xeris Biopharma presently has an average rating of "Moderate Buy" and a consensus price target of $6.10.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.